Search

A 54-year-old man developed Sweet's syndrome while being treated with bictegravir/emtricitabine/tenofovir alafenamide for HIV-1 infection. He experienced symptoms such as cough, difficulty breathing, excessive sweating, and loss of appetite, along with skin lesions on his upper limbs. After being admitted to the hospital, Sweet's syndrome was diagnosed and attributed to the medication. The treatment was discontinued, and the man received corticosteroids, leading to improvement and discharge after five days. [Extracted from the article]

A 54-year-old man developed Sweet's syndrome while being treated with bictegravir/emtricitabine/tenofovir alafenamide for HIV-1 infection. He experienced symptoms such as cough, difficulty breathing, excessive sweating, and loss of appetite, along with skin lesions on his upper limbs. After being admitted to the hospital, Sweet's syndrome was diagnosed and attributed to the medication. The treatment was discontinued, and the man received corticosteroids, leading to improvement and discharge after five days. [Extracted from the article]

A 35-year-old woman developed hypophosphataemic osteochondrosis dissecans after receiving treatment with adefovir for chronic hepatitis B. Initially, she presented with low back pain and walking difficulties, and her physical examination revealed positive tests for ankylosing spondylitis. However, further tests and imaging revealed that her symptoms were actually caused by the long-term use of adefovir, which mimicked ankylosing spondylitis. After discontinuing adefovir and starting new medications, her condition improved and her blood levels returned to normal. [Extracted from the article]

A 35-year-old woman developed hypophosphataemic osteochondrosis dissecans after receiving treatment with adefovir for chronic hepatitis B. Initially, she presented with low back pain and walking difficulties, and her physical examination revealed positive tests for ankylosing spondylitis. However, further tests and imaging revealed that her condition was actually caused by long-term use of adefovir. She was subsequently treated with different medications and her condition improved. Adefovir was discontinued and she was started on other medications, leading to a gradual normalization of her blood levels. [Extracted from the article]

A 55-year-old man developed Fanconi syndrome and osteomalacia while being treated with tenofovir disoproxil fumarate for chronic hepatitis B. He experienced symptoms such as weakness, weight loss, nausea, vomiting, lack of appetite, and bone pain. Physical examination revealed cachexia, chest deformation, and swelling of the lower limbs. After discontinuing the treatment and switching to entecavir, the man's symptoms resolved and his test results returned to normal. [Extracted from the article]

A 29-year-old man with chronic hepatitis B and advanced stage hepatocellular carcinoma experienced lack of efficacy during treatment with glucose for non-islet cell tumor hypoglycemia. Despite high dose, continuous glucose infusion, his severe hypoglycemia persisted. The hypoglycemia was found to be caused by non-islet cell tumor hypoglycemia and worsened tumor invasion of the liver. The patient's hypoglycemia was eventually controlled with the use of unspecified corticosteroids and parenteral nutrition with high amounts of glucose. [Extracted from the article]

A 61-year-old woman with chronic hepatitis B and untreated low grade B-cell lymphoma experienced lack of efficacy during treatment with methylprednisolone-sodium-succinate and immune-globulin for paraneoplastic neurological syndrome (PNS). Despite receiving these medications, her visual and neurological symptoms did not improve. Further investigations revealed that she also had a small bowel diverticulum. The final diagnosis was anti-Ma2 antibody-mediated paraneoplastic cerebellar degeneration and myeloneuropathy attributed to B-cell lymphoma. The patient was eventually discharged after starting rituximab, cyclophosphamide, vincristine, and prednisone. [Extracted from the article]

In a retrospective cohort study, two patients with chronic hepatitis-B (CHB) were found to be non-responders to therapy with peginterferon. The study included 77 patients with CHB who were enrolled between January 2007 and August 2020. The lack of response to peginterferon therapy indicates a lack of efficacy in these patients. One patient was of European descent and the other was of Mediterranean descent. [Extracted from the article]

A 53-year-old man developed drug resistance while being treated with tecovirimat for monkeypox virus infection. The man had multiple underlying health conditions, including HIV, chronic hepatitis B, and other infections. Initially, his symptoms improved with tecovirimat treatment, but his anal lesions did not fully resolve and viral shedding continued. It was determined that he had developed resistance to tecovirimat, and his treatment was extended, although the outcome is not specified. [Extracted from the article]

A 30-year-old woman experienced gastrointestinal side effects and nausea while being treated for generalized plaque psoriasis and chronic hepatitis B infection. She also did not respond well to several medications for her psoriasis and misused some of them. Despite trying different treatments, her symptoms persisted until she was diagnosed with chronic hepatitis B and started taking tenofovir, which significantly improved her psoriasis. However, she eventually discontinued tenofovir due to nausea. [Extracted from the article]

A man in his 50s developed drug resistance to lamivudine while being treated for hepatitis-B liver cirrhosis. He also developed Fanconi's syndrome, which led to complications such as osteomalacia, avascular necrosis, fracture, hypophosphatemia, and dementia. The patient's condition worsened over time, and he experienced depression, memory impairment, and parkinsonism features. It was concluded that the Fanconi's syndrome was a result of the medications he was taking. Unfortunately, his dementia remained irreversible, and he continued to require assistance with walking. [Extracted from the article]

A 31-year-old man experienced persistent hiccups and lack of efficacy while being treated for somatic symptom disorder. He had a history of chronic hepatitis B and was taking various medications, including aripiprazole, oxazepam, anisodamine, baclofen, and metoclopramide. Despite trying different treatments, his hiccups persisted and caused significant disruption to his sleep and anxiety levels. Eventually, his aripiprazole therapy was discontinued, and he was treated with chlorpromazine, which provided relief from the hiccups. Psychological suggestion therapy was also used to address the issue. [Extracted from the article]

A case report published in the journal Reactions Weekly describes a 65-year-old man who experienced a lack of efficacy and developed alopecia universalis while being treated with sintilimab for hepatocellular carcinoma (HCC). The man had a history of chronic viral hepatitis B and liver cirrhosis, but no previous dermatological disease or family history of alopecia areata. Despite treatment with sintilimab, a new tumor was detected, leading to the discontinuation of the drug. After four weeks of treatment, the man experienced extensive hair loss, which was diagnosed as alopecia universalis and lasted for 21 months. However, after discontinuing sintilimab, some hair regrowth was observed. Pathological examination revealed an enhanced adaptive immune response throughout the body. [Extracted from the article]

A 34-year-old man developed autoimmune-like drug-induced liver injury after misusing thiamazole for Graves' disease. He also experienced rebound liver injury after stopping prednisone acetate treatment. Treatment with ursodeoxycholic acid for the liver injury was ineffective. The man received various treatments, including entecavir for chronic hepatitis B, acetylcysteine and ademetionine-butandisulphonate for liver injury, and iodine-131 for Graves' disease. After multiple treatments, his condition improved and he eventually recovered without recurrence. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 59-year-old woman developed Fanconi syndrome during treatment with tenofovir disoproxil fumarate for chronic hepatitis B and C infection. Additionally, she exhibited no response during treatment with potassium for severe hypokalaemia [not all routes stated; dosages and duration of treatment to reaction onset not stated]. [Extracted from the article]

A 50-year-old man with chronic hepatitis B (CHB) infection was diagnosed with stage-B hepatocellular carcinoma (HCC) and underwent surgery. However, the HCC recurred and metastasized, leading to treatment with lenvatinib. Unfortunately, the lenvatinib treatment was ineffective, and the patient's disease progressed. As a second-line treatment, the patient received sintilimab and regorafenib, but experienced gum bleeding, diarrhea, and bloody stools as side effects. Despite these toxicities, the patient's treatment with sintilimab and regorafenib continued. [Extracted from the article]

A 47-year-old man with a history of chronic hepatitis B developed skin peeling while being treated with sorafenib for hepatocellular carcinoma (HCC). He then started receiving nivolumab in addition to sorafenib and developed fulminant liver failure. The patient was hospitalized and received methylprednisolone and plasma exchange therapy, which led to rapid improvement. After discharge, his liver function normalized during outpatient visits. [Extracted from the article]

Subsequently, they developed renal failure (1 patient), osteoporosis (1 patient) and persistent headache (1 patient). The patients, who were diagnosed with chronic hepatitis B, started receiving oral lamivudine (1 patient), oral entecavir (2 patient) and oral tenofovir disoproxil fumarate (1 patient). Therefore, treatment with lamivudine switched to tenofovir alafenamide (1 patient), entecavir switched to oral tenofovir disoproxil fumarate (1 patient) and remaining two patients with tenofovir disoproxil fumarate (1 patient) and entecavir (1 patient) switched to unspecified treatment regimen. [Extracted from the article]

Case 2: The mother of the fetus who had chronic hepatitis B (CHB), had been receiving treatment with tenofovir-disoproxil-fumarate for CHB during her pregnancy. Case 7: The mother of the infant who had chronic hepatitis B (CHB), had been receiving treatment with tenofovir-disoproxil-fumarate for CHB during her pregnancy. Case 6: The mother of the infant who had chronic hepatitis B (CHB), had been receiving treatment with tenofovir-disoproxil-fumarate for CHB during her pregnancy. [Extracted from the article]

In December 2021, reduced lung metastases and no recurrence of the liver tumor were noted. Lung metastases after liver cancer resection cured by immunotherapy: case report and literature review. However, increased lung metastasis tumor and AFP level were noted, indicating lack of efficacy to fluorouracil, folinic-acid, oxaliplatin and rivoceranib. [Extracted from the article]

The patient, who had CHB, started receiving treatment with tenofovir disoproxil fumarate at a dose 300 mg/day. Tenofovir disoproxil fumarate for patients with chronic hepatitis B who suboptimal response to non-tenofovir disoproxil fumarate nucleos(t)ide analogs therapy. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a retrospective study of 248 patient with chronic hepatitis B (CHB) conducted between September 2011 and December 2018 in Taiwan, one patient [ I age and sex not stated i ] was described, who developed deterioration of renal function during treatment with tenofovir disoproxil fumarate for CHB [ I route not stated i ]. [Extracted from the article]

Novel hepatitis B virus reverse transcriptase mutations in patients with sustained viremia despite long-term tenofovir treatment. Additionally, the man (patient 2) exhibited lack of efficacy to lamivudine for HIV associated hepatitis B virus (HBV) infection [ I routes not stated i ]. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a study 2 adult men [ I exact ages not stated i ] were described, who developed drug resistance to entecavir, tenofovir alafenamide or tenofovir disoproxil fumarate for treatment of chronic hepatitis B (CHB). [Extracted from the article]

Case report: Primary hepatocellular carcinoma with portal vein tumor thrombus characterized by active tumor immune microenvironment achieving a complete response following treatment of combined immunotherapy. Laboratory examinations imaging studies were performed, and he was diagnosed with hepatocellular carcinoma with portal vein tumor thrombus. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 59-year-old man exhibited lack-of-efficacy during the treatment with sorafenib for primary hepatocellular carcinoma with portal vein tumour thrombus. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 44-year-old man developed hepatic portal venous gas, liver damage and liver abscess during treatment with iodised oil and pirarubicin during transcatheter arterial chemoembolization (TACE). Additionally, he exhibited lack of efficacy to anti-infective treatment with piperacillin/tazobactam [ I not all duration of treatment to reaction onset stated i ]. A chest CT scan revealed pneumonia in the right lung pneumorachis with iodine oil deposition in the tumor lesion in the right lobe of the liver that was considered as hepatic abscess. [Extracted from the article]

Subsequently, he was diagnosed with intracerebral haemorrhage (ICH) and stroke [ I aetiology not stated i ]. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a case series of two patient, et al. 77-year-old man (case B) was described, who experienced worsened hypertension during treatment with lenvatinib for hepatocellular carcinoma [ I route, dosage and time to reaction onset not stated i ]. He developed perihaematomal oedema of ICH and received celecoxib therapy. [Extracted from the article]

During fifth pregnancy, she received bemiparin-sodium, folic-acid and aspirin for prophylactic anticoagulation to prevent pregnancy loss [ I not all routes and dosages stated i ]. Prophylactic anticoagulation was initiated to prevent pregnancy loss at 5 weeks of gestation with nadroparin-calcium 2850U daily, which continued until 12 weeks of gestation. She received aspirin until 36 weeks of gestation, bemiparin-sodium was discontinuation 24h prior to scheduled cesarean section at 39-40 weeks of gestation. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 42-year-old woman exhibited lack of efficacy during treatment with cisplatin and lenvatinib for hepatocellular carcinoma (HCC). Subsequently, she developed mild encephalitis/encephalopathy with a reversible splenial lesion (MERS) during treatment with atezolizumab and bevacizumab for HCC [ I not all routes and dosages stated i ]. [Extracted from the article]

The woman's therapy with adefovir dipivoxil was switched to entecavir with a significant improvement in bone pain after phosphates and vitamin D. A month later, pain in joints and ribs disappeared. Severe hypophosphataemic osteomalacia related to low-dose adefovir dipivoxil therapy in a hepatitis B virus patient. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 47-year-old woman developed hypophosphataemic osteomalacia during treatment with adefovir dipivoxil for hepatitis B [ I route and duration of treatment to reaction onset not stated i ]. [Extracted from the article]

After 18 months, no contrast enhancement of the portal vein tumor thrombosis and splenic metastasis was noted. Four years after the initial hepatectomy, she developed liver tumor. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 63-year-old woman developed diarrhoea during treatment with lenvatinib; additionally, she exhibited a lack of efficacy following treatment with regorafenib for liver tumor [ I routes and dosages not stated i ]. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 26-year-old man developed peripheral neuropathy during treatment with linezolid for pre-extensively drug-resistant (XDR) tuberculosis. However, despite the treatment, no improvement was noted in his condition after four months of treatment indicating lack of efficacy for the therapy. He also exhibited lack of efficacy during treatment with bedaquiline, linezolid, moxifloxacin, cycloserine and clofazimine for the XDR-tuberculosis, and with pyridoxine, thiamine, mecobalamin, pregabalin, gabapentin and tramadol for neuropathic pain [ I routes and dosages not stated i ]. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event * First published case report A 53-year-old man developed I Mycobacterium neoaurum i ( I M. neoaurum i ) bacteraemia, catheter-associated bloodstream infection (CABI) due to I M. neoaurum i and exacerbation of psoriasis during treatment with camrelizumab for hepatocellular carcinoma (HCC). Case report: Mycobacterium neoaurum infection during ICI therapy in a hepatocellular carcinoma patient with psoriasis. [Extracted from the article]

Her medical history included more than 20 year history of chronic viral hepatitis B and denied family history of cancer or any relevant genetic history. Based on further investigations, she was diagnosed with pT2N1M0, IIB, luminal B type ILC of right breast. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 56-year-old woman exhibited a lack of efficacy during treatment with exemestane for pT2N1M0, IIB, luminal B type invasive lobular carcinoma (ILC) of right breast. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 39-year-old woman exhibited lack of efficacy during treatment with daunorubicin and cytarabine for acute myeloid leukaemia. Examination revealed multiple fetal congenital anomalies including hypotelorism, mid-facial deformity, absence of nasal bone, cleft lip and palate, rocker-bottom feet and polydactyly. [Extracted from the article]

The patients were diagnosed with CHB and started receiving lamivudine (2 patients), lamivudine + entecavir (1 patient) and lamivudine + adefovir (2 patients). B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a retrospective study of 39 patients, five men aged 39-60 years old were described, who developed acquired resistance during treatment with lamivudine, adefovir or entecavir for chronic hepatitis B (CHB). Subsequently, they showed resistant mutations to lamivudine (L180M and M204V in 1 patient and M204I in another patient), entecavir ( L180M, M204V, I169T, T184L in 1 patient) and lamivudine + adefovir (M204I and A181T, N236T in 1 patient and remaining patient showed M204I and A181V). [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 44-year-old man exhibited lack of efficacy during treatment with tafamidis meglumine for transthyretin-gene (TTR) familial amyloid polyneuropathy (FAP). Clinical improvement after change of therapy from tafamidis to patisiran in progressive TTR amyloidosis post-liver transplantation. Tafamidis meglumine therapy did not stop disease progression, indicating lack of efficacy. [Extracted from the article]

He had no subjective complaints and his biological profile was otherwise normal except for lymphopenia 0.6 × 10 SP 9 sp /L. The diagnosis of hepatitis-B reactivation secondary to ruxolitinib was made. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 79-year-old man experienced hepatitis B virus (HBV) reactivation during treatment with ruxolitinib for secondary myelofibrosis [ I route, dosage and duration of treatment to reaction onset not stated i ]. In August 2019, he presented with abnormal liver function tests, and further investigation confirmed a diagnosis of hepatitis-B reactivation with positive viraemia 1.9 × 10 SP 7 sp IU/mL and newly positive HBsAg. [Extracted from the article]